**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 30250**

**Manuscript Type: REVIEW**

Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases

Ceuleers H *et al.* Proteases and visceral hypersensitivity

Hannah Ceuleers, Hanne Van Spaendonk, Nikita Hanning, Jelena Heirbaut, Anne-Marie Lambeir, Jurgen Joossens, Koen Augustyns, Joris G De Man, Ingrid De Meester, Benedicte Y De Winter

Hannah Ceuleers, Hanne Van Spaendonk, Nikita Hanning, Jelena Heirbaut, Joris G De Man, Benedicte Y De Winter, Laboratory of Experimental Medicine and Pediatrics, Division of Gastroenterology, University of Antwerp, 2610 Antwerp, Belgium

Anne-Marie Lambeir, Ingrid De Meester, Laboratory of Medical Biochemistry, University of Antwerp, 2610 Antwerp, Belgium

Jurgen Joossens, Koen Augustyns, Laboratory of Medicinal Chemistry and Antwerp Drug Discovery Network, University of Antwerp, 2610 Antwerp, Belgium

Author contributions: All authors contributed equally to this paper with conception and design of the study, literature review and analysis, drafting and critical review and editing and approval of the final version.

Supported by University Research Fund Doctoral Projects (BOF-DOCPRO), No. DOCPRO4 2014/ID 2964; and Research Foundation Flanders (FWO), No. G034113N.

Conflict-of-interest statement: No potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

Correspondence to: Benedicte Y De Winter, Professor, MD, PhD, Laboratory of Experimental Medicine and Pediatrics, Division of Gastroenterology, University of Antwerp, Universiteitsplein 1, 2610 Antwerpen, Belgium. benedicte.dewinter@uantwerpen.be

**Telephone:** +32-3-2652710

**Fax:** +32-3-2652567

**Received:** September 21, 2016

**Peer-review started:** September 22, 2016

**First decision**: October 20, 2016

**Revised:** November 10, 2016

**Accepted:** December 2, 2016

**Article in press:**

**Published online:**

Abstract
Proteases, enzymes catalyzing the hydrolysis of peptide bonds, are present at high concentrations in the gastrointestinal tract. Besides their well-known role in the digestive process, they also function as signaling molecules through the activation of protease-activated receptors (PARs). Based on chemical mechanism for catalysis, proteases can be classified into several classes: serine, cysteine, aspartic, metallo and threonine proteases represent the mammalian protease families. In particular, the class of serine proteases will play a significant role in this review. In the last decades, proteases have been suggested to play a key role in the pathogenesis of visceral hypersensitivity, which is a major factor contributing to abdominal pain in patients with inflammatory bowel diseases and/or irritable bowel syndrome. So far, only a few preclinical animal studies have investigated the effect of protease inhibitors specifically on visceral sensitivity while their effect on inflammation is described in more detail. In our accompanying review we describe their effect on gastrointestinal permeability. On account of their promising results in the field of visceral hypersensitivity, further research is warranted. The aim of this review is to give an overview on the concept of visceral hypersensitivity as well as on the physiological and pathophysiological functions of proteases herein.

**Key words:** Proteases; Proteinase-activated receptors; Protease inhibitors; Visceral hypersensitivity; Visceral pain; Irritable bowel syndrome; Inflammatory bowel diseases

**©The Author(s) 2016**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Proteases are enzymes catalyzing the hydrolysis of peptide bonds. They are present at high levels in the gastrointestinal tract and they execute a large variety of physiological and pathophysiological functions. In the last decade, it became clear that proteases fulfill an important role in visceral pain, a major symptom in patients with inflammatory bowel diseases and/or irritable bowel syndrome. These review articles aim at providing an overview of the diverse roles of proteases in both health and disease states related to the gastrointestinal functions, with the emphasis on visceral pain in this review.

Ceuleers H, Van Spaendonk H, Hanning N, Heirbaut J,Lambeir AM, De Man JG, De Meester I, De Winter BY**.** Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. *World J Gastroenterol* 2016; In press

INTRODUCTION

Abdominal pain is a key feature of two major gastrointestinal disorders, inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS). On the one hand, IBD, such as ulcerative colitis (UC) and Crohn’s Disease (CD), are characterized by acute flares of inflammation followed by periods of remission[[1](#_ENREF_1)]. On the other hand, IBS is a functional disorder defined by the presence of altered bowel habits and abdominal pain, in the absence of any organic cause[[2](#_ENREF_2)]. The diagnosis of IBS is based on the Rome IV criteria: recurrent abdominal pain for at least 3 days/month in the last 3 months associated with two or more of the following symptoms: (1) improvement with defecation; (2) onset associated with a change in frequency of stool; and (3) onset associated with a change in form (appearance) of stool[[2](#_ENREF_2),[3](#_ENREF_3)]. Currently four IBS subtypes are defined based on the predominant stool pattern: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M) and unsubtyped IBS (IBS-U)[[2](#_ENREF_2)]. Both IBD and IBS have an increasing prevalence; IBD affects up to 1.5 million people in the United States of America and 2.2 million Europeans[[4](#_ENREF_4)], whereas IBS has a worldwide prevalence of 11.2%[[5](#_ENREF_5)]. Although IBD and IBS are regarded as two different diseases, they seem to be related: the prevalence of IBS-like symptoms in IBD patients with an active disease and in IBD patients in remission amounts to 44% and 35%, respectively[[6](#_ENREF_6),[7](#_ENREF_7)]. Besides being highly prevalent, these disorders have a considerable impact through their chronic character, as well as a negative influence on the quality of life and an important socio-economic impact[[8](#_ENREF_8),[9](#_ENREF_9)]. Furthermore, the current treatment options are mostly focusing on the reduction of inflammation for IBD or the motility disturbances for IBS. Only a few therapies aim directly at diminishing the abdominal pain. Remarkably, only 24% of the IBS patients report complete relief of abdominal pain after treatment which is mostly only a symptomatic treatment of the most explicit motility-related symptom[[8](#_ENREF_8)]. Therefore, further research in this area is of utmost importance. However, the search for new treatment targets is hampered due to the incomplete understanding of the pathogenesis of visceral pain.

Visceral hypersensitivity, or an increased pain perception in the bowel, is an important factor underlying the abdominal pain in IBS[[10](#_ENREF_10)]. Visceral hypersensitivity occurs via a disturbance of the sensitization pathways that might be located at different levels. At the peripheral level, chemical, mechanical and thermal information is registered by primary afferent neurons. The cell bodies of these neurons are located in the dorsal root ganglia (DRGs)[[11](#_ENREF_11)]. Centrally, they connect with secondary afferent neurons in the dorsal horn of the spinal cord or in the brain stem. From there, the signal is transduced to different cerebral areas involved in the somatosensory sensation of (pain) signals arising from the bowel. Within the central nervous system, signals of peripheral afferent nerves are modulated *via* descending pathways, resulting in facilitation or inhibition of the impulse conduction[[12](#_ENREF_12)]. For a complete overview of the neuroanatomy of lower gastrointestinal pain disorders, we like to refer the interested readers to a review by Vermeulen *et al*[[13](#_ENREF_13)].

During gastrointestinal inflammation, the continuous release of inflammatory mediators can give rise to the sensitization of peripheral afferent nerves, thus contributing to the development of visceral hypersensitivity. Besides being an important well-known trigger for IBD, (microscopic) inflammation has been demonstrated to play a role in IBS as well. As already mentioned, an increased prevalence of IBS-like symptoms is present in IBD patients. Moreover, a disease state denominated as post-infectious IBS has been described; it is seen in 3%-35% of the patients that experienced an acute gastroenteritis related to water contamination[[14](#_ENREF_14)]. These observations suggest a strong association between gastrointestinal inflammation on the one hand and the onset of visceral hypersensitivity on the other hand, in which case the hypersensitivity persists even after complete resolution of the inflammation.

At the peripheral level, inflammatory cells, *e.g.,* mast cells, T-cells and neutrophils, are activated. Upon activation, they release excessive amounts of inflammatory mediators such as histamine, serotonin, several cytokines and proteases. These mediators, in turn, can sensitize peripheral afferent neurons, thus contributing to visceral hypersensitivity. The role of most of these inflammatory mediators in visceral hypersensitivity has been investigated extensively[[7](#_ENREF_7)]{De Schepper, 2008 #23}. However, the role of proteases is not fully elucidated yet. Therefore, the aim of this review is to focus on proteases and their physiological role as well as their role in the pathophysiology of visceral hypersensitivity. In an accompanying paper by Van Spaendonk *et al*. we discussed the role of proteases in intestinal permeability.

**VISCERAL HYPERSENSITIVITY**

Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by altered bowel habits and abdominal pain. This visceral pain – pain originating from internal organs such as the gut – is typically vague, diffuse, poorly localized and often associated with referred pain[[15](#_ENREF_15)]. Visceral hypersensitivity is the main mechanism underlying this abdominal pain[[16](#_ENREF_16)]. Hypersensitivity refers to the increased sensation of stimuli: both allodynia (pain evoked by stimuli that are normally not painful) and hyperalgesia (increased response to a painful stimulus) are present[[17](#_ENREF_17)]. In both basic and clinical research, visceral hypersensitivity is commonly investigated by colorectal balloon distensions using a barostat [[18](#_ENREF_18)]. Compared to healthy individuals, patients suffering from visceral hypersensitivity report discomfort at lower colonic distension pressures (lower pain threshold) and increased pain in response to standardized stimuli[[17](#_ENREF_17)]. Currently, the pathophysiology of visceral hypersensitivity has not been fully elucidated yet, but several mechanisms, such as inflammation, psychosocial factors and/or sensorimotor alterations, are thought to be involved. The latter can be located both at the central and/or peripheral level along the anatomical afferent information pathway from the viscera towards the brain. Moreover, an important role for peripheral as well as central sensitization of the afferent visceral neuron pathways is proposed[[19](#_ENREF_19)].

The mast cell is thought to fulfill an important task in the development of abdominal pain in IBS patients[[20](#_ENREF_20)], since an association was found between mast cell infiltration in the bowel wall and the frequency and severity of abdominal pain[[21](#_ENREF_21)]. The mast cell is an important immune cell that can be activated by cytokines, antigens and neuropeptides. This activation is followed by a degranulation of the cell, releasing vasoactive and pro-inflammatory mediators[[16](#_ENREF_16)]. Histamine, an important mast cell mediator, has already been shown to play an important role in visceral hypersensitivity: we demonstrated a role for histamine in a rat model for post-inflammatory visceral hypersensitivity, mediated by histamine H1 and H4 receptors[[22](#_ENREF_22)]. Also in humans, a recent clinical trial with the H1 receptor-antagonist ebastine showed promising results in IBS patients resulting in a phase II trial (www.clinicaltrials.gov)[[23](#_ENREF_23)]. Apart from histamine, mast cells release many other mediators such as cytokines, growth factors, leukotrienes, prostaglandins, serotonin and several proteases[[24](#_ENREF_24)]. In this review, we will focus on the role of this last group of mediators, the proteases, and their role in visceral hypersensitivity. In the accompanying paper the role in intestinal permeability is addressed.

PROTEASES

Proteases are enzymes catalyzing the hydrolysis of peptides and/or proteins, thereby releasing amino acids or peptides. They represent up to 2% of the human genome and are present at particularly high levels in the gastrointestinal tract[[25](#_ENREF_25)]. Proteases execute a large variety of physiological functions. They are vital for processes such as blood coagulation, cell growth and migration, tissue arrangement, activation of zymogens, protein catabolism and the release of hormones and pharmacologically active peptides from precursor proteins. Apart from that, they are involved in pathological processes such as inflammation and tumor growth and metastasis[[26](#_ENREF_26),[27](#_ENREF_27)].

Based on the position of the peptide bond that can be cleaved, proteases are subdivided into two major groups: exopeptidases and endopeptidases. Exopeptidases catalyze the cleavage of the terminal or the penultimate peptide bond of the protein, releasing a single amino acid or a dipeptide, respectively [[28](#_ENREF_28), [29](#_ENREF_29)]. Since peptide chains have both an amino- and a carboxy-terminus, exopeptidases can be further divided into amino- and carboxypeptidases[[28](#_ENREF_28)]. Aminopeptidases could release a single amino acid, a dipeptide or a tripeptide from the N-terminus, while carboxypeptidases can liberate an amino acid or a dipeptide from the C-terminus[[30](#_ENREF_30)]. Unlike exopeptidases, endopeptidases catalyze the cleavage of nonterminal peptide bonds within the molecule, thus releasing larger peptides instead of single amino acids, dipeptides or tripeptides[[28](#_ENREF_28),[29](#_ENREF_29)]. The concept of exo- and endopeptidases is represented in a simplified way in Figure 1.

Due to their huge diversity in action and structure, proteases can be classified in other ways as well[[27](#_ENREF_27)]. For example, it is possible to classify the enzymes according to their evolutionary relatedness with reference to structure, the type of reaction catalyzed or the pH optimum of the enzyme[[27](#_ENREF_27)]. However, they are usually categorized according to their catalytic type, based upon the presence of different nucleophiles in the molecular structure of the enzyme[[28](#_ENREF_28)-[32](#_ENREF_32)]. The major advantage of using a catalytic type based classification is that proteases of the same catalytic type usually respond to the same protease inhibitors[[32](#_ENREF_32)]. Historically, four major groups could be distinguished in this classification, based upon the functional group present at the active site: serine, cysteine, aspartic and metalloproteases[[29](#_ENREF_29), [31](#_ENREF_31)]. More recently, threonine, glutamate and asparagine proteases have been added as classes. However, glutamate and asparagine proteases have not been found in humans or other mammals so far[[32](#_ENREF_32)]. The seven catalytic classes are depicted in Figure 2. In the last decades, proteases have come into the picture as a new target for drug development. An overview of the protease inhibitors approved for clinical use can be found in a Nature review by Turk *et al*[[33](#_ENREF_33)]. Concerning visceral hypersensitivity, serine proteases are thought to be an important class[[34](#_ENREF_34)]. Some examples of serine protease inhibitors that were already tested in clinical trials are summarized in Table 1, thereby emphasizing the widespread indications. Proteases can also act as signaling molecules; they regulate cell functions by modulating protease-activated receptors (PARs). PARs belong to a family of cell-surface signaling proteins called G protein-coupled receptors (GPCRs) and consist of seven transmembrane domains with three intracellular and three extracellular protein loops[[25](#_ENREF_25),[35](#_ENREF_35)], as visualized in Figure 3. So far, four PARs have been described: PAR1, PAR2, PAR3 and PAR4[[36](#_ENREF_36)].

 PARs have been found in various cell types throughout the whole gastrointestinal tract. Remarkably, a great overlap can be detected in the cell types expressing PAR1 and PAR2. PAR1 and PAR2 have already been described in enterocytes, neurons, fibroblasts, mast cells, smooth muscle cells, endothelium and immune cells. On the other hand, PAR4 has only been identified in enterocytes, neurons, endothelium and immune cells. Furthermore, PAR3 has been identified in stomach and small intestine but the exact cell types still need to be defined. For a complete overview of the location of the different PARs in the gastrointestinal tract, we would like to refer to a review by Vergnolle *et al*[[37](#_ENREF_37)].

PARs can transduce signals by *canonical activation*. The activation process starts with a protease recognizing one of the extracellular domains of the receptor, situated on the N-terminus (*i.e.,* the *canonical site* of the PAR receptor). Some proteases, such as thrombin, subsequently bind to this domain. For other proteases, *e.g.,* trypsin or tryptase, it is not required to establish a stable bond in order to cleave the receptor. When the receptor has been activated, the N-terminal domain will be cleaved by proteolysis at the recognition site, thus exposing a new N-terminal sequence. This sequence acts as a tethered ligand that binds domains situated in the second extracellular loop of the receptor, thus initiating common signaling pathways, such as the G-protein- and/or β-arrestin-dependent pathways (*e.g.,* PAR2 activation by trypsin)[[25](#_ENREF_25),[38](#_ENREF_38)]. The activation process is visualized in Figure 3.

Apart from canonical activation, PAR signaling pathways can be initiated in several other ways. *Biased agonism* is a second possibility; proteases cleave at sites distinct from the canonical sites, thereby activating unique and biased signaling pathways (*e.g.,* PAR2 activation by activated protein C)[[38](#_ENREF_38)]. Proteases are also able to induce the opposite effect; this third manner is called *proteolytic disarming*. In that case, proteases can remove or destroy tethered ligands leading to the termination of PAR activation (*e.g.,* PAR2 disarming by cathepsin-G)[[36](#_ENREF_36),[38](#_ENREF_38)]. A fourth manner is the *non-tethered ligand activation*, suggesting that the formation of tethered ligands is not essential for PAR activation (*e.g.,* PAR2 activation by elastase). Finally, it is possible to activate PARs via so-called PAR-activating peptides (PAR-APs), synthetic peptides corresponding to the first five or six amino acids of the tethered ligand sequence. This form of artificial activation bypasses the proteolytic cleaving process. PAR-APs are capable of inducing common as well as biased signaling pathways (*e.g.,* PAR2 activation by SLIGKV-NH2)[[38](#_ENREF_38),[39](#_ENREF_39)]. Since these peptides are specific for a single receptor, they are very important pharmacological tools to investigate the physiology and physiopathology of PARs[[36](#_ENREF_36)].

Currently, thrombin is regarded as the main activator for PAR1, PAR3 and PAR4, as is the serine protease trypsin for PAR2 and PAR4. Although some proteases can activate different PARs, every protease has a preference for one specific receptor. For example, thrombin has the highest potency for PAR1, a lower potency for PAR3, and even weaker for PAR4[[25](#_ENREF_25)]. For an overview of the characteristics of the four PARs, their activating proteases and agonists/antagonists, we refer to a detailed and excellent review by Vergnolle *et al*[[37](#_ENREF_37)].

**PROTEASES, PROTEASE-ACTIVATED RECEPTORS AND PROTEASE INHIBITORS IN VISCERAL HYPERSENSITIVITY**

***Proteases***

So far, the expression and activity of proteases in the colon and feces of IBS patients have not been investigated intensively. A higher expression of the serine proteases tryptase[[21](#_ENREF_21),[40-44](#_ENREF_40)] and trypsin[[40](#_ENREF_40),[41](#_ENREF_41)] as well as the cysteine protease calpain-8[[45](#_ENREF_45)] was described in colonic biopsy samples of IBS patients compared to healthy controls. However, no changes in tryptase expression (protein level) could be detected in fecal samples of IBS patients[[46](#_ENREF_46),[47](#_ENREF_47)]. Serine protease activity was increased in IBS patients compared to healthy controls in both colon and feces in several studies[[40](#_ENREF_40), [47-49](#_ENREF_47)]. Likewise, an elevated serine protease activity was observed in colonic samples in a post-infectious IBS mouse model [[50](#_ENREF_50)]. Taken together all the studies described above, an important role for serine proteases in IBS cannot be denied. However, the origin of those serine proteases was unclear for a long time. Recently, the Spiller group published a paper demonstrating the human (and not bacterial) origin of the most abundant fecal serine proteases in IBS-D patients[[51](#_ENREF_51)]. Cystein protease activity was elevated in fecal samples of IBS-C patients[[52](#_ENREF_52)], although this alteration could not be observed in colonic samples of post-infectious IBS mice[[50](#_ENREF_50)]. Recently, concerns have been raised about the tests used to determine the protease activity. Many of these tools suffer from a lack of selectivity for individual proteases and most of them detect several enzymes. For example, when determining tryptase-activity, mostly trypsin-like activity is quantified due to the lack of specificity of the substrates used[[53](#_ENREF_53)]. Therefore, with regard to a detailed study of the role of proteases in *e.g.,* visceral hypersensitivity, the improvement of chemical tools to assess the activity of specific proteases is of utmost importance[[53](#_ENREF_53)].

***Protease-activated receptors***

Proteases are thought to influence visceral sensitivity through protease-activated receptors (PARs). Remarkably, after the activation of these receptors, the effects on pain are not the same for all PARs. When PAR1 and PAR4 are activated, antinociceptive effects are observed, while the activation of PAR2 induces pronociceptive effects. An overview of the studies described in the following paragraph is shown in Table 2.
The antinociceptive properties of PAR1 activation are demonstrated in different animal models showing a decrease in carrageenan-induced visceral hyperalgesia in rats and capsaicin-evoked visceral pain in mice after an intraplantar administration with the PAR1-agonists TFFLR-NH2 and thrombin[[54](#_ENREF_54),[55](#_ENREF_55)]. In mice, PAR4 activation seems to inhibit visceral hypersensitivity as well[[48](#_ENREF_48),[56](#_ENREF_56)]. In parallel, PAR4 expression is lowered in the colon of IBS patients[[41](#_ENREF_41),[57](#_ENREF_57)]. The PAR4-agonist AYPGKF-NH2 was able to reduce visceral hypersensitivity after an intracolonic administration in sub-inflammatory doses, while higher doses showed pro-inflammatory effects in mice[[56](#_ENREF_56)].

In sharp contrast to PAR1 and PAR4, the activation of PAR2 results in a pronociceptive effect. This was firstly demonstrated by Kawabata *et al*[[58](#_ENREF_58)]and Coelho *et al*[[59](#_ENREF_59)] who confirmed the presence of visceral hypersensitivity in rats after the administration (intracolonic/intraplantar) of the the PAR2-activating peptide SLIGRL-NH2 or trypsin. An increased Fos-expression[[59](#_ENREF_59)] and the presence of PAR2 mRNA in the dorsal root ganglia (DRG)[[58](#_ENREF_58)] confirmed these results. An *ex-vivo* study reconfirmed these observations: the application of several PAR2-agonists, such as trypsin, mast cell tryptase and SL-NH2, induced hyperexcitability of submucosal neurons in the ileum of guinea pigs[[60](#_ENREF_60)]. The next step in this research included the use of experimental knock-out (KO) models. Similar to the studies described above, visceral hyperalgesia was observed in wild-type (WT) mice after the administration (intracolonic/intraplantar) of PAR2-activating peptides such as 2-furoyl-LIGRL-NH2 and trypsin. However, these effects were reduced in PAR2-KO mice[[61](#_ENREF_61),[62](#_ENREF_62)]. The effects described above were confirmed using IBS-patient supernatant, which is a well-known alternative stimulus for visceral pain in experimental animal models. Murine sensory neurons in culture were sensitized after the addition of IBS patient supernatant, while this effect was absent in neurons from the KO mice lacking PAR2. Furthermore, this supernatant caused visceral hypersensitivity in WT mice, but not in mice treated with a PAR2-antagonist or in PAR2-KO mice[[40](#_ENREF_40)]. Also, the IBS-D supernatant was able to enhance the neuronal excitability of colonic DRGs in WT but not in PAR2-KO mice, again demonstrating the importance of PAR2[[63](#_ENREF_63)]. Based on these literature data we can conclude that the effects of proteases on visceral pain following PAR activation is dependent on the type of receptor involved: PAR1 and PAR4 evoke antinociceptive effects while the activation of PAR2 results in pronociception.

***Protease inhibitors***

So far research groups in the field of visceral hypersensitivity have mainly focused on PAR-knockout experiments, while protease inhibitors have been investigated to a lesser extent. In this paragraph, an overview of the studies exploring the effects of protease inhibitors in visceral hypersensitivity, is given. All protease inhibitors, with their respective targets, are listed in Table 3. Nafamostat mesilate or FUT-175 is a broad specificity serine protease inhibitor. In mice, visceral hypersensitivity induced by the intracolonic infusion of IBS-D fecal supernatants, could be suppressed when the supernatant was pre-incubated with nafamostat mesilate[[64](#_ENREF_64)]. Similar results were observed by the group of Cenac *et* *al*[[40](#_ENREF_40)]who used a similar, but slightly different experimental design. They used the supernatant of biopsies of IBS patients instead of fecal samples and apart from a decrease in visceral hypersensitivity, they also observed less sensitization of murine neurons after a pre-incubation with nafamostat mesilate. We recently demonstrated a positive effect of a single intraperitoneal injection of nafamostat mesilate in a trinitrobenzenesulfonic acid (TNBS)-induced rat model for both acute and post-inflammatory visceral hypersensitivity[[65](#_ENREF_65),[66](#_ENREF_66)]. Furthermore, the newly developed serine protease inhibitor benzyl N-1-[bis(4-acetamidophenoxy)phosphoryl]-2-(4-carbamimidamidophenyl)ethyl-carbamate (SPIx) showed anti-nociceptive properties as well, both in an acute and in a post-inflammatory setting[[65](#_ENREF_65),[66](#_ENREF_66)]. Camostat mesilate, another serine protease inhibitor with structural properties similar to nafamostat mesilate showed analogous results. Intragastric pre-treatment with camostat mesilate decreased hypersensitivity in rats with visceral hypersensitivity induced by acute restraint stress as well as spinal c-Fos expression (an indirect marker of neuronal activity) and fecal protease activity[[67](#_ENREF_67),[68](#_ENREF_68)]. Also in an acute TNBS colitis model, which is a preclinical model for IBD, positive results were observed on visceral hypersensitivity after treatment with different protease inhibitors. Moussa *et al*[[69](#_ENREF_69)] found a decrease in visceral sensitivity, fecal protease activity and PAR2 expression in acute TNBS colitis rats treated with a fermented soy germ extract, containing phytoestrogens (isoflavones) and serine protease inhibitors (Bowman-Birk Inhibitor). However, the effects on visceral sensitivity were completely reversed by simultaneous treatment with an estrogen receptor antagonist, suggesting that the effects were mostly attributed to the phytoestrogens. The same group also demonstrated the positive effect of phytoestrogens on hypersensitivity in another animal model: this time, stress-induced hypersensitivity in female rats could be prevented by a treatment with either estradiol benzoate or fermented soy germ extract. Again this time, the positive effects were abolished after concomitant administration of an estrogen receptor antagonist[[70](#_ENREF_70)].

In sharp contrast to the hypersensitivity seen in mice after an intracolonic infusion with fecal IBS-D supernatant, fecal supernatant of UC patients evoked hyposensitivity to colorectal distension. In IBS-D, PAR2 is stimulated due to the increased fecal serine protease activity, resulting in hypersensitivity. In addition, the activation of PAR4, by adding Cathepsin-G (Cat-G) to the supernatant, reversed this effect. Hyposensitivity could be observed after the infusion of a UC supernatant most likely because PAR4 (activated by Cat-G) is predominantly activated. However after the inhibition of PAR4 or Cat-G hypersensitivity appeared and the addition of the serine protease inhibitors aprotinin/SBTI normalized sensitivity[[48](#_ENREF_48)]. Based on these studies by Annaházi *et al*[[48](#_ENREF_48)] the importance of the equilibrium between the activation of PAR2 and PAR4 in visceral sensitivity was clearly shown. To summarize this paragraph, the limited amount of data available regarding protease inhibitors and visceral pain show promising results. However, only a few broad specificity inhibitors were investigated and in a majority of the studies, a preventive treatment scheme was used. Thus, this topic needs to be further explored.

**CONCLUSION**

The pharmacological treatment of gastrointestinal disorders such as IBD and IBS remains a challenge and until today, mainly focuses on symptomatic control. One of the biggest challenges is the management of visceral hypersensitivity, which is seen as the mechanism behind abdominal pain. In the last decades, many possible pharmacological targets have been proposed, but unfortunately an effective, causative treatment is still lacking. Therefore, further elucidating the pathophysiology of visceral hypersensitivity and eventually discovering new possible pharmacological targets is of great importance. Recently, serine proteases have come into the picture as a promising new pharmacological target for visceral pain. Up until now, research has focused mainly on PAR-agonists/antagonists, but none of these compounds made it to the clinic yet. A more recent strategy is the direct inhibition of serine proteases, which shows promising results in a limited number of animal experiments in the field of visceral hypersensitivity. So far, serine protease inhibitors have not been tested in clinical trials for IBS either. However, serine protease inhibitors are well known in the treatment of other diseases, e.g. diabetes and pancreatic cancer. In the domain of gastroenterology, protease inhibitors have already been investigated in animal models, focusing on the effects on intestinal inflammation and permeability. Protease inhibitors were able to ameliorate inflammation as well as permeability, suggesting that proteases may be valuable treatment targets. The few preclinical studies investigating the effect of protease inhibitors on visceral hypersensitivity show promising results. Therefore it seems necessary that more in-depth research on the therapeutic potential of protease inhibitors in abdominal pain is conducted in the upcoming years. The emphasis should be on the detection and eventually the targeting of specific proteases that might be crucial in visceral hypersensitivity. First of all, as proteases often have overlapping substrate specificities and specific inhibitors are in many cases not available, the methods used to measure the activity of individual proteases should be improved. Furthermore, more and better validated tools are needed to quantify their protein levels. Measuring specific protease activities remains a great challenge. However, investigating the link between certain protease activities and IBS-subtypes would be of great interest and could possibly lead towards the discovery of a new drug target or the development of a new biomarker. Concerning therapeutic options we need to take into account that IBS is not considered to be a life-threatening disease and thus medication needs to be free of substantial side effects. This is certainly an important consideration given the various functions of proteases in the human body, and yet another reason to focus on the specificity of protease inhibitors, thereby not forgetting the potential importance of the equilibrium between proteases and anti-proteases. Direct inhibition of proteases has already been put forward as a possible strategy for the treatment of visceral hypersensitivity in IBS patients. Therefore, we believe that the development of new and more specific protease inhibitors could be of great interest. In the future, not only the safety profile of these compounds but also their route of administration will become a very important subject. Up until now, protease inhibitors are administered via systemic routes, but ideally, the treatment of IBS should focus on the gastrointestinal tract in a further attempt to reduce systemic side-effects. A serine protease inhibitor for local delivery is unfortunately not available at this time and it would be groundbreaking if researchers came up with a solution for this problem. In a recent article from Bermúdez-Humarán, a revolutionary method using recombinant lactic acid bacteria (recLAB) to deliver serine protease inhibitors (Elafin and Secretory Leukocyte Protease Inhibitor- SLPI) at the mucosal level, is described[[71](#_ENREF_71)]. However, it should be taken into account that in this case the serine protease inhibitors had a protein structure and therefore recombinant bacteria were able to produce and express them. Other serine protease inhibitors such as nafamostat mesilate are synthetic compounds with an organic chemical structure and thus cannot be produced by recombinant bacteria. Therefore, research groups should come up with new strategies to deliver synthetic compounds at the mucosal level. In our opinion, in the following years, research groups should focus on the development of specific serine protease inhibitors, taking into account the potentiality of delivering that compound at the level of the colonic mucosa after correctly measuring the specific protease profile of the individual patient, allowing individually tailored therapy.

# REFERENCES

1 **Podolsky DK**. Inflammatory bowel disease. *N Engl J Med* 2002; **347**: 417-429 [PMID: 12167685 DOI: 10.1056/NEJMra020831]

2 **Chey WD**, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA* 2015; **313**: 949-958 [PMID: 25734736 DOI: 10.1001/jama.2015.0954]

3 **Drossman DA**. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. *Gastroenterology* 2016; Epub ahead of print [PMID: 27144617 DOI: 10.1053/j.gastro.2016.02.032]

4 **Ananthakrishnan AN**. Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 205-217 [PMID: 25732745 DOI: 10.1038/nrgastro.2015.34]

5 **Lovell RM**, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol* 2012; **10**: 712-721.e4 [PMID: 22426087 DOI: 10.1016/j.cgh.2012.02.029]

6 **Halpin SJ**, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol* 2012; **107**: 1474-1482 [PMID: 22929759 DOI: 10.1038/ajg.2012.260]

7 **De Schepper HU**, De Man JG, Moreels TG, Pelckmans PA, De Winter BY. Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease - clinical relevance and pathophysiological mechanisms. *Aliment Pharmacol Ther* 2008; **27**: 621-637 [PMID: 18221407 DOI: 10.1111/j.1365-2036.2008.03624.x]

8 **Hungin AP**, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. *Aliment Pharmacol Ther* 2003; **17**: 643-650 [PMID: 12641512]

9 **Spiller R**. Clinical update: irritable bowel syndrome. *Lancet* 2007; **369**: 1586-1588 [PMID: 17499587 DOI: 10.1016/S0140-6736(07)60726-0]

10 **Barbara G**, Cremon C, De Giorgio R, Dothel G, Zecchi L, Bellacosa L, Carini G, Stanghellini V, Corinaldesi R. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. *Curr Gastroenterol Rep* 2011; **13**: 308-315 [PMID: 21537962 DOI: 10.1007/s11894-011-0195-7]

11 **Blackshaw LA**, Brookes SJ, Grundy D, Schemann M. Sensory transmission in the gastrointestinal tract. *Neurogastroenterol Motil* 2007; **19**: 1-19 [PMID: 17280582 DOI: 10.1111/j.1365-2982.2006.00871.x]

12 **Anand P**, Aziz Q, Willert R, van Oudenhove L. Peripheral and central mechanisms of visceral sensitization in man. *Neurogastroenterol Motil* 2007; **19**: 29-46 [PMID: 17280584 DOI: 10.1111/j.1365-2982.2006.00873.x]

13 **Vermeulen W**, De Man JG, Pelckmans PA, De Winter BY. Neuroanatomy of lower gastrointestinal pain disorders. *World J Gastroenterol* 2014; **20**: 1005-1020 [PMID: 24574773 DOI: 10.3748/wjg.v20.i4.1005]

14 **Marshall JK**, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. *Gut* 2010; **59**: 605-611 [PMID: 20427395 DOI: 10.1136/gut.2009.202234]

15 **Sikandar S**, Dickenson AH. Visceral pain: the ins and outs, the ups and downs. *Curr Opin Support Palliat Care* 2012; **6**: 17-26 [PMID: 22246042 DOI: 10.1097/SPC.0b013e32834f6ec9]

16 **Akbar A**, Walters JR, Ghosh S. Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents. *Aliment Pharmacol Ther* 2009; **30**: 423-435 [PMID: 19493256 DOI: 10.1111/j.1365-2036.2009.04056.x]

17 **Camilleri M**, Coulie B, Tack JF. Visceral hypersensitivity: facts, speculations, and challenges. *Gut* 2001; **48**: 125-131 [PMID: 11115834]

18 **Keszthelyi D**, Troost FJ, Masclee AA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome. *Am J Physiol Gastrointest Liver Physiol* 2012; **303**: G141-G154 [PMID: 22595988 DOI: 10.1152/ajpgi.00060.2012]

19 **de Carvalho Rocha HA**, Dantas BP, Rolim TL, Costa BA, de Medeiros AC. Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome. *Ann Gastroenterol* 2014; **27**: 200-206 [PMID: 24976114]

20 **De Winter BY**, van den Wijngaard RM, de Jonge WJ. Intestinal mast cells in gut inflammation and motility disturbances. *Biochim Biophys Acta* 2012; **1822**: 66-73 [PMID: 21497195 DOI: 10.1016/j.bbadis.2011.03.016]

21 **Barbara G**, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004; **126**: 693-702 [PMID: 14988823]

22 **Deiteren A**, De Man JG, Ruyssers NE, Moreels TG, Pelckmans PA, De Winter BY. Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity. *Gut* 2014; **63**: 1873-1882 [PMID: 24561612 DOI: 10.1136/gutjnl-2013-305870]

23 **Wouters MM**, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar YA, Valdez-Morales EE, Nasser Y, Van Veldhoven PP, Vanbrabant W, Van der Merwe S, Mols R, Ghesquière B, Cirillo C, Kortekaas I, Carmeliet P, Peetermans WE, Vermeire S, Rutgeerts P, Augustijns P, Hellings PW, Belmans A, Vanner S, Bulmer DC, Talavera K, Vanden Berghe P, Liston A, Boeckxstaens GE. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.*Gastroenterology* 2016; **150**: 875-87.e9 [PMID: 26752109 DOI: 10.1053/j.gastro.2015.12.034]

24 **Zhang L**, Song J, Hou X. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. *J Neurogastroenterol Motil* 2016; **22**: 181-192 [PMID: 26755686 DOI: 10.5056/jnm15137]

25 **Vergnolle N**. Modulation of visceral pain and inflammation by protease-activated receptors. *Br J Pharmacol* 2004; **141**: 1264-1274 [PMID: 15051630 DOI: 10.1038/sj.bjp.0705750]

26 **Antalis TM**, Shea-Donohue T, Vogel SN, Sears C, Fasano A. Mechanisms of disease: protease functions in intestinal mucosal pathobiology. *Nat Clin Pract Gastroenterol Hepatol* 2007; **4**: 393-402 [PMID: 17607295 DOI: 10.1038/ncpgasthep0846]

27 **Rao MB**, Tanksale AM, Ghatge MS, Deshpande VV. Molecular and biotechnological aspects of microbial proteases. *Microbiol Mol Biol Rev* 1998; **62**: 597-635 [PMID: 9729602]

28 **Hooper NM**. Proteases: a primer. *Essays Biochem* 2002; **38**: 1-8 [PMID: 12463157]

29 **Barrett AJ**. The many forms and functions of cellular proteinases. *Fed Proc* 1980; **39**: 9-14 [PMID: 6985872]

30 **Barrett AJ.** Classification of peptidases. Methods in Enzymology 1994; **244**: 1-15 [PMID: 7845199]

31 **Powers JC**, Odake S, Oleksyszyn J, Hori H, Ueda T, Boduszek B, Kam C. Proteases--structures, mechanism and inhibitors. *Agents Actions Suppl* 1993; **42**: 3-18 [PMID: 8356929]

32 **Rawlings ND**, Barrett AJ, Bateman A. Asparagine peptide lyases: a seventh catalytic type of proteolytic enzymes. *J Biol Chem* 2011; **286**: 38321-38328 [PMID: 21832066 DOI: 10.1074/jbc.M111.260026]

33 **Turk B**. Targeting proteases: successes, failures and future prospects. *Nat Rev Drug Discov* 2006; **5**: 785-799 [PMID: 16955069 DOI: 10.1038/nrd2092]

34 **Vergnolle N**. Protease inhibition as new therapeutic strategy for GI diseases. *Gut* 2016; **65**: 1215-1224 [PMID: 27196587 DOI: 10.1136/gutjnl-2015-309147]

35 **Cenac N**, Garcia-Villar R, Ferrier L, Larauche M, Vergnolle N, Bunnett NW, Coelho AM, Fioramonti J, Bueno L. Proteinase-activated receptor-2-induced colonic inflammation in mice: possible involvement of afferent neurons, nitric oxide, and paracellular permeability. *J Immunol* 2003; **170**: 4296-4300 [PMID: 12682265]

36 **Cenac N**. Protease-activated receptors as therapeutic targets in visceral pain. *Curr Neuropharmacol* 2013; **11**: 598-605 [PMID: 24396336 DOI: 10.2174/1570159X113119990039]

37 **Vergnolle N**. Clinical relevance of proteinase activated receptors (pars) in the gut. *Gut* 2005; **54**: 867-874 [PMID: 15888798 DOI: 10.1136/gut.2004.048876]

38 **Zhao P**, Metcalf M, Bunnett NW. Biased signaling of protease-activated receptors. *Front Endocrinol* (Lausanne) 2014; **5**: 67 [PMID: 24860547 DOI: 10.3389/fendo.2014.00067]

39 **Hollenberg MD**, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. *Pharmacol Rev* 2002; **54**: 203-217 [PMID: 12037136]

40 **Cenac N**, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. *J Clin Invest* 2007; **117**: 636-647 [PMID: 17304351 DOI: 10.1172/JCI29255]

41 **Zhao JH**, Dong L, Shi HT, Wang ZY, Shi HY, Ding H. The expression of protease-activated receptor 2 and 4 in the colon of irritable bowel syndrome patients. *Dig Dis Sci* 2012; **57**: 58-64 [PMID: 21800160 DOI: 10.1007/s10620-011-1827-3]

42 **Buhner S**, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann M. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. *Gastroenterology* 2009; **137**: 1425-1434 [PMID: 19596012 DOI: 10.1053/j.gastro.2009.07.005]

43 **Liang WJ,** Zhang G, Luo HS, Liang LX, Huang D, Zhang FC. Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome. *Gut Liver* 2016; **10**: 382-390 [PMID: 26446924 DOI: 10.5009/gnl14319]

44 **Bian ZX**, Li Z, Huang ZX, Zhang M, Chen HL, Xu HX, Sung JJ. Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients. *J Gastroenterol* 2009; **44**: 666-674 [PMID: 19430717 DOI: 10.1007/s00535-009-0058-2]

45 **Swan C**, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG, Neal KR, Whorwell PJ, Hall IP, Spiller RC. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. *Gut* 2013; **62**: 985-994 [PMID: 22684480 DOI: 10.1136/gutjnl-2011-301213]

46 **Lettesjö H**, Hansson T, Peterson C, Ung KA, Ringström G, Abrahamsson H, Simrén M. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. *Scand J Gastroenterol* 2006; **41**: 54-59 [PMID: 16373277 DOI: 10.1080/00365520510023909]

47 **Róka R**, Rosztóczy A, Leveque M, Izbéki F, Nagy F, Molnár T, Lonovics J, Garcia-Villar R, Fioramonti J, Wittmann T, Bueno L. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. *Clin Gastroenterol Hepatol* 2007; **5**: 550-555 [PMID: 17336590 DOI: 10.1016/j.cgh.2006.12.004]

48 **Annaházi A**, Gecse K, Dabek M, Ait-Belgnaoui A, Rosztóczy A, Róka R, Molnár T, Theodorou V, Wittmann T, Bueno L, Eutamene H. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. *Pain* 2009; **144**: 209-217 [PMID: 19450926 DOI: 10.1016/j.pain.2009.04.017]

49 **Gecse K**, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A, Izbéki F, Fioramonti J, Wittmann T, Bueno L. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. *Gut* 2008; **57**: 591-599 [PMID: 18194983 DOI: 10.1136/gut.2007.140210]

50 **Ibeakanma C**, Ochoa-Cortes F, Miranda-Morales M, McDonald T, Spreadbury I, Cenac N, Cattaruzza F, Hurlbut D, Vanner S, Bunnett N, Vergnolle N, Vanner S. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. *Gastroenterology* 2011; **141**: 2098-2108.e5 [PMID: 21856270 DOI: 10.1053/j.gastro.2011.08.006]

51 **Tooth D**, Garsed K, Singh G, Marciani L, Lam C, Fordham I, Fields A, Banwait R, Lingaya M, Layfield R, Hastings M, Whorwell P, Spiller R. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit. *Gut* 2014; **63**: 753-760 [PMID: 23911555 DOI: 10.1136/gutjnl-2012-304042]

52 **Annaházi A**, Ferrier L, Bézirard V, Lévêque M, Eutamène H, Ait-Belgnaoui A, Coëffier M, Ducrotté P, Róka R, Inczefi O, Gecse K, Rosztóczy A, Molnár T, Ringel-Kulka T, Ringel Y, Piche T, Theodorou V, Wittmann T, Bueno L. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. *Am J Gastroenterol* 2013; **108**: 1322-1331 [PMID: 23711626 DOI: 10.1038/ajg.2013.152]

53 **Edgington-Mitchell LE**. Pathophysiological roles of proteases in gastrointestinal disease. *Am J Physiol Gastrointest Liver Physiol* 2016; **310**: G234-G239 [PMID: 26702140 DOI: 10.1152/ajpgi.00393.2015]

54 **Kawao N**, Ikeda H, Kitano T, Kuroda R, Sekiguchi F, Kataoka K, Kamanaka Y, Kawabata A. Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. *J Pharmacol Sci* 2004; **94**: 277-285 [PMID: 15037813]

55 **Kawabata A**, Kawao N, Kuroda R, Tanaka A, Shimada C. The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats. *Peptides* 2002; **23**: 1181-1183 [PMID: 12126749]

56 **Augé C**, Balz-Hara D, Steinhoff M, Vergnolle N, Cenac N. Protease-activated receptor-4 (PAR 4): a role as inhibitor of visceral pain and hypersensitivity. *Neurogastroenterol Motil* 2009; **21**: 1189-e107 [PMID: 19413681 DOI: 10.1111/j.1365-2982.2009.01310.x]

57 **Han W**, Wang Z, Lu X, Guo C. Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome. *Neurogastroenterol Motil* 2012; **24**: 113-19, e82 [PMID: 22151913 DOI: 10.1111/j.1365-2982.2011.01841.x]

58 **Kawabata A**, Kawao N, Kuroda R, Tanaka A, Itoh H, Nishikawa H. Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. *Neuroreport* 2001; **12**: 715-719 [PMID: 11277570]

59 **Coelho AM**, Vergnolle N, Guiard B, Fioramonti J, Bueno L. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. *Gastroenterology* 2002; **122**: 1035-1047 [PMID: 11910355]

60 **Reed DE**, Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Dery O, Grady EF, Bunnett NW, Vanner SJ. Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons. *J Physiol* 2003; **547**: 531-542 [PMID: 12562962 DOI: 10.1113/jphysiol.2002.032011]

61 **Vergnolle N**, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G, Gerard N, Basbaum AI, Andrade-Gordon P, Hollenberg MD, Wallace JL. Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. *Nat Med* 2001; **7**: 821-826 [PMID: 11433347 DOI: 10.1038/89945]

62 **Kawabata A**, Kawao N, Kitano T, Matsunami M, Satoh R, Ishiki T, Masuko T, Kanke T, Saito N. Colonic hyperalgesia triggered by proteinase-activated receptor-2 in mice: involvement of endogenous bradykinin. *Neurosci Lett* 2006; **402**: 167-172 [PMID: 16644120 DOI: 10.1016/j.neulet.2006.03.074]

63 **Valdez-Morales EE**, Overington J, Guerrero-Alba R, Ochoa-Cortes F, Ibeakanma CO, Spreadbury I, Bunnett NW, Beyak M, Vanner SJ. Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. *Am J Gastroenterol* 2013; **108**: 1634-1643 [PMID: 23958521 DOI: 10.1038/ajg.2013.241]

64 **Wang P**, Chen FX, Du C, Li CQ, Yu YB, Zuo XL, Li YQ. Increased production of BDNF in colonic epithelial cells induced by fecal supernatants from diarrheic IBS patients. *Sci Rep* 2015; **5**: 10121 [PMID: 25998025 DOI: 10.1038/srep10121]

65 **Ceuleers H**, Segaert E, Heirbaut J, Hanning N, Francque SM, Joossens J, De Meester I, De Man J, De Winter BY. Su1937 Two Serine Protease Inhibitors, Nafamostat Mesylate and the Newly Developed SPIx, Decrease Post-Inflammatory Visceral Hypersensitivity in Rats. *Gastroenterology* 2016; **150**: S593-S4 [DOI: 10.1016/S0016-5085(16)32036-4]

66 **Ceuleers H,** De Man JG, Deiteren A, De Schepper H, Joossens J, Francque S. The effect of a potent tryptase inhibitor and a new serine protease inhibitor on visceral pain in a rat model of acute colitis. Friday, 5 June 2015 08: 30–10: 00 Hall B2 FP-01 Sensory mechanisms. *Neurogastroenterol Motility* 2015; **27**: 22-25 [DOI: 10.1111/nmo.12597]

67 **Zhao J**, Wang J, Dong L, Shi H, Wang Z, Ding H, Shi H, Lu X. A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats. *Eur J Pharmacol* 2011; **654**: 289-294 [PMID: 21237151 DOI: 10.1016/j.ejphar.2010.12.032]

68 **Zhao J**, Wang Z, Zou B, Song Y, Dong L. [Camostat mesilate, a protease inhibitor, inhibits visceral sensitivity and spinal c-fos expression in rats with acute restraint stress]. *Nan Fang Yi Ke Da Xue Xue Bao* 2014; **34**: 1546-1550 [PMID: 25345960]

69 **Moussa L**, Bézirard V, Salvador-Cartier C, Bacquié V, Lencina C, Lévêque M, Braniste V, Ménard S, Théodorou V, Houdeau E. A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease. *PLoS One* 2012; **7**: e49547 [PMID: 23166707 DOI: 10.1371/journal.pone.0049547]

70 **Moussa L**, Bézirard V, Salvador-Cartier C, Bacquié V, Houdeau E, Théodorou V. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats. *Clin Nutr* 2013; **32**: 51-58 [PMID: 22727545 DOI: 10.1016/j.clnu.2012.05.021]

71 **Bermúdez-Humarán LG**, Motta JP, Aubry C, Kharrat P, Rous-Martin L, Sallenave JM, Deraison C, Vergnolle N, Langella P. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. *Microb Cell Fact* 2015; **14**: 26 [PMID: 25889561 DOI: 10.1186/s12934-015-0198-4]

72 **Mavrakanas TA**, Chatzizisis YS. Bivalirudin in stable angina and acute coronary syndromes. *Pharmacol Ther* 2015; **152**: 1-10 [PMID: 25857452 DOI: 10.1016/j.pharmthera.2015.04.003]

73 **Reddy P**, Giugliano RP. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. *J Cardiovasc Pharmacol Ther* 2014; **19**: 526-532 [PMID: 24659084 DOI: 10.1177/1074248414525505]

74 **McCormack PL**. Edoxaban: a review in nonvalvular atrial fibrillation. *Am J Cardiovasc Drugs* 2015; **15**: 351-361 [PMID: 26369340 DOI: 10.1007/s40256-015-0148-x]

75 **Fanola CL**. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. *Vasc Health Risk Manag* 2015; **11**: 271-282 [PMID: 26064057 DOI: 10.2147/VHRM.S62595]

76 **Fujii K**, Kanno Y, Konishi K, Ohgou N. A specific thrombin inhibitor, argatroban, alleviates herpes zoster-associated pain. *J Dermatol* 2001; **28**: 200-207 [PMID: 11449671]

77 **Armstrong WB**, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. *Cancer Prev Res* (Phila) 2013; **6**: 410-418 [PMID: 23639862 DOI: 10.1158/1940-6207.CAPR-13-0004]

78 **Scully M**, Gates C, Neave L. How we manage patients with heparin induced thrombocytopenia. *Br J Haematol* 2016; **174**: 9-15 [PMID: 27097741 DOI: 10.1111/bjh.14102]

79 **Heinemann V**, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. *Br J Cancer* 2013; **108**: 766-770 [PMID: 23412098 DOI: 10.1038/bjc.2013.62]

80 **Uwagawa T**, Misawa T, Tsutsui N, Ito R, Gocho T, Hirohara S, Sadaoka S, Yanaga K. Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. *Am J Clin Oncol* 2013; **36**: 44-48 [PMID: 22157216 DOI: 10.1097/COC.0b013e31823a53b2]

81 **Bao P**, Zhao W, Li Y, Liu Y, Zhou Y, Liu C. Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: a randomized, placebo-controlled study. *Med Oncol* 2015; **32**: 405 [PMID: 25502081 DOI: 10.1007/s12032-014-0405-x]

82 **Narra K**, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. *Cancer Biol Ther* 2007; **6**: 1691-1699 [PMID: 18032930]

83 **Zhang L**, Wang N, Zhou S, Ye W, Yao Q, Jing G, Zhang M. Preventive effect of ulinastatin on postoperative complications, immunosuppression, and recurrence in esophagectomy patients. *World J Surg Oncol* 2013; **11**: 84 [PMID: 23575450 DOI: 10.1186/1477-7819-11-84]

84 **Krishna MT**, Chauhan A, Little L, Sampson K, Hawksworth R, Mant T, Djukanovic R, Lee T, Holgate S. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. *J Allergy Clin Immunol* 2001; **107**: 1039-1045 [PMID: 11398082 DOI: 10.1067/mai.2001.115631]

85 **Strange C**, Beiko T. Treatment of Alpha-1 Antitrypsin Deficiency. *Semin Respir Crit Care Med* 2015; **36**: 470-477 [PMID: 26238635 DOI: 10.1055/s-0035-1555608]

86 **Twigg MS**, Brockbank S, Lowry P, FitzGerald SP, Taggart C, Weldon S. The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis Lung. *Mediators Inflamm* 2015; **2015**: 293053 [PMID: 26185359 DOI: 10.1155/2015/293053]

87 **Thomas MC**, Paldánius PM, Ayyagari R, Ong SH, Groop PH. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Ther* 2016; **7**: 439-454 [PMID: 27502495 DOI: 10.1007/s13300-016-0189-4]

88 **Royston D**. The current place of aprotinin in the management of bleeding. *Anaesthesia* 2015; **70** Suppl 1: 46-9, e17 [PMID: 25440394 DOI: 10.1111/anae.12907]

89 **Ono S**, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. *Am J Surg* 1999; **177**: 78-82 [PMID: 10037314]

90 **Inagaki H**, Nonami T, Kurokawa T, Takeuchi Y, Okuda N, Nakao A, Sakamoto J. Effects of nafamostat mesilate, a synthetic protease inhibitor, on immunity and coagulation after hepatic resection. *Hepatogastroenterology* 1999; **46**: 3223-3228 [PMID: 10626190]

91 **Ito H**, Nakayama H, Yokose T, Yamada K. Prophylaxis for acute exacerbation of interstitial pneumonia after lung resection. *Asian Cardiovasc Thorac Ann* 2014; **22**: 948-954 [PMID: 24585320 DOI: 10.1177/0218492314526187]

92 **Joossens J**, Ali OM, El-Sayed I, Surpateanu G, Van der Veken P, Lambeir AM, Setyono-Han B, Foekens JA, Schneider A, Schmalix W, Haemers A, Augustyns K. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. *J Med Chem* 2007; **50**: 6638-6646 [PMID: 18052026 DOI: 10.1021/jm700962j]

**P-Reviewer:** Ghannam A, Ksiazek M, Lakatos PL **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Belgium

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Simplified representation of the concept of endo- and exopeptidases.** Endopeptidases cleave internal peptide bonds. Exopeptidases cleave terminal peptide bonds; they can be subdivided into amino- and carboxypeptidases according to the position of the cleavage of the peptide bond. Aminopeptidases cleave at amino (NH2) terminal bonds, while carboxypeptidases cleave at carboxy (COOH) terminal bonds. Image constructed using the Servier Image Bank.



**Figure 2 Classification of proteases based on the chemical structure of their active site.** For each class, the chemical structure of the core residue in their active site is shown on top and a few examples with medical relevance of proteases belonging to that family are displayed below. MMP: Matrix metalloprotease.



**Figure 3 Schematic representation of the activation of a protease-activated receptor.** A protease cleaves the N-terminal domain (1), releasing a new N-terminus (2). The new N-terminus binds to the receptor as a tethered ligand, providing an intracellular signal (3). Image constructed using the Servier Image Bank. N-terminus: Amino-terminus; PAR: Protease-activated receptor.

**Table 1 Serine protease inhibitors (mammalian): examples of clinical applications in different organ systems**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Category** | **Indication** | **Serine protease inhibitor *(target)*** | **Status** | **Ref.** |
| Cardiovascular | ACS | Bivalirudin *(thrombin)* | Approved | [[72](#_ENREF_72)] |
| AF | Rivaroxaban *(factor Xa)* | Approved | [[73](#_ENREF_73)] |
| Edoxaban *(factor Xa)* | Approved | [[74](#_ENREF_74)] |
| VTE | Dabigatran *(thrombin)* | Approved | [[75](#_ENREF_75)] |
| Dermatology | Herpes zoster | Argatroban *(thrombin)* | Clinical – phase II | [[76](#_ENREF_76)] |
| Oral leukoplakia | BBIC *(broad specificity)* | Clinical – phase II | [[77](#_ENREF_77)] |
| Hematology | Heparin-induced thrombocytopenia | Argatroban *(thrombin)* | ApprovedApproved | [[78](#_ENREF_78)] |
| Fondaparinux *(factor Xa)* |
| Oncology | Pancreatic cancer: CTx | Upamostat *(uPA)* | Clinical – phase IIClinical – phase II | [[79](#_ENREF_79)] |
| Nafamostat mesilate *(broad specificity)* | [[80](#_ENREF_80)] |
| Lung cancer: RTx | Ulinastatin *(broad specificity)* | Clinical – phase unknown | [[81](#_ENREF_81)] |
| Colorectal cancer: CTx | Talabostat *(fibroblast activating protein)* | Clinical – phase II | [[82](#_ENREF_82)] |
| Esophegal cancer: Sx | Ulinastatin *(broad specificity)* | Clinical – phase unknown | [[83](#_ENREF_83)] |
| PneumologyEndocrinology | Asthma | APC 366 *(mast cell tryptase)* | Clinical – phase II | [[84](#_ENREF_84)] |
| α1 antitrypsin deficiency | α1 antitrypsin *(broad specificity)* | Approved | [[85](#_ENREF_85)] |
| Cystic fibrosisDiabetes  | α1 antitrypsin *(broad specificity)* | Clinical – phase IIApproved | [[86](#_ENREF_86)][[87](#_ENREF_87)] |
| Gliptins *(DPP-IV)*1 |
| Surgery | N/A | Aprotinin *(broad specificity)* | ApprovedClinical – Phase IIIClinical – Phase IVClinical – Phase unknown | [[88](#_ENREF_88)] |
| Gabexate mesilate (*broad specificity)* | [[89](#_ENREF_89)] |
| Nafamostat mesilate *(broad specificity)* | [[90](#_ENREF_90)] |
| Sivelestat *(neutrophil elastase)* | [[91](#_ENREF_91)] |

1DPP-IV is a non-classical serine protease belonging to family S9: prolyl oligopeptidase (novel class). Literature search in Pubmed (last updated Sept 19 2016) with MeSH terms *serine protease inhibitor – dpp-4 inhibitor - clinical trials – English – human.* ACS: Acute coronary syndrome; A: Atrial fibrillation; BBIC: Bowman Birk inhibitor concentrate; BHR: Bronchial hyperresponsiveness; cf.: Compared to; CTx,: Chemotherapy; DPP-IV: Dipeptidylpeptidase IV; EAR: Early asthmatic response; GP: Glycoprotein IIb/IIIa inhibitor; ICH: Intracranial hemorrhage; LAR: Late asthmatic response; PA: Protease activity; PI: Protease inhibitor; POC: Postoperative complications; RTx: Radiotherapy; SIRS: Systemic inflammatory respiratory syndrome; Sx: Surgery; uPA: Urokinase plasminogen activator; VTE: Venous thromboembolism.

**Table 2 Preclinical studies investigating the effects of protease-activated receptor-targeting molecules on visceral hypersensitivity**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **PAR** | **Agonist/antagonist** | **Species *(hypersensitivity model)*** | **Study type** | **Effect** | **Ref.** |
| PAR-1 | Agonist (thrombin, TFLLR-NH2) | Rat *(carrageenan)* | *In vivo* | ↓ hyperalgesia | [[55](#_ENREF_55)] |
| PAR-1 | Agonist (TFLLR-NH2) | Mice *(capsaicin)* | *In vivo* | ↓ hyperalgesia | [[54](#_ENREF_54)] |
| PAR-2 | Agonist (SLIGRL-NH2) | Mice *(PAR2-agonist)* | *In vivo* | ↑ hyperalgesia | [[58](#_ENREF_58)] |
| PAR-2 | Agonist (SLIGRL-NH2, trypsin) | Rat *(PAR2-agonist)* | *In vivo* | ↑ hyperalgesia | [[59](#_ENREF_59)] |
| PAR-2 | Agonist (SL-NH2, trypsin, typtase) | Guinea pig submucosal neurons *(PAR2-agonist)* | *Ex vivo* | ↑ neuron excitability | [[60](#_ENREF_60)] |
| PAR-2 | Agonist (SLIGRL-NH2, Tc-NH2, trypsin, tryptase) | Mice, rat *(PAR2-agonist)* | KO | ↑ hyperalgesia, absent in KO | [[61](#_ENREF_61)] |
| PAR-2 | Agonist (2-furoyl-LIGRL-NH2) | Mice *(capsaicin)* | KO | ↑ hyperalgesia, absent in KO | [[62](#_ENREF_62)] |
| PAR-2 | Antagonist (ENMD-1068) | Mice *(IBS-supernatant)* | KO | ↓ hypersensitivity, absent in KO | [[40](#_ENREF_40)] |
| PAR-2 | / | Mice DRG *(IBS-D supernatant)* | KO | ↑ neuron excitability, absent in KO | [[63](#_ENREF_63)] |
| PAR-4 | Agonist (PAR-4-AP, Cat-G) | Mice *(IBS-D supernatant)* | *In vivo* | ↓ hypersensitivity | [[48](#_ENREF_48)] |
| PAR-4 | Agonist (AYPGKF-NH2) | Mice *(PAR2-agonist, TRPV4-agonist)* | *In vivo* | ↓ hypersensitivity | [[56](#_ENREF_56)] |

DRG: Dorsal root ganglia; IBS: Irritable bowel syndrome; KO: Knock-out; PAR: Protease-activated receptor; TRPV: Transient receptor potential vanilloid channels.

**Table 3 Serine protease inhibitors investigated in experimental visceral hypersensitivity models**

|  |  |  |
| --- | --- | --- |
| **Inhibitor name** | **Target(s)** | **Ref.** |
| Aprotinin | Chymotrypsin, elastase, KLK, plasmin, PA, trypsin, urokinase, XIIa | [[48](#_ENREF_48)] |
| Bowman-Birk inhibitor | Chymotrypsin, trypsin | [[69](#_ENREF_69),[70](#_ENREF_70)] |
| Camostat mesilate (FOY-305) | Trypsin, matriptase, prostasin, plasmin, tPA, uPA, Xa, IXa, thrombin, tissue factor, complement factors, tryptase, HNE, KLK | [[67](#_ENREF_67),[68](#_ENREF_68)] |
| Cathepsin-G inhibitor | Cathepsin G | [[48](#_ENREF_48)] |
| Nafamostat mesilate (FUT-175) | Tryptase, trypsin, C1r, C1s, thrombin, kallikrein, plasmin | [[36](#_ENREF_36),[64-66](#_ENREF_64)] |
| Serine protease inhibitor x (SPIx) | Tryptase, matriptase, KLK4, KLK8, uPA | [[65](#_ENREF_65),[66](#_ENREF_66),[92](#_ENREF_92)] |
| Soybean trypsin inhibitor (SBTI) | Trypsin, chymotrypsin, plasmin, kallikrein, Xa | [[48](#_ENREF_48)] |

C1r: Complement component 1r; C1s: Complement component 1s; HNE: 4-hydoxynonenal; KLK: Kallikrein;
PA: plasminogen activator; tPA: Tissue plasminogen activator; uPA: Urokinase plasminogen activator.